{
    "title": "Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4312748/Novartis-wins-U-S-approval-breast-cancer-drug-compete-Pfizers-Ibrance.html",
    "date": "2017-03-14",
    "keywords": [
        "kisqali",
        "approval",
        "company",
        "ibrance",
        "monitoring",
        "novartis",
        "drug",
        "breast",
        "cancer",
        "patient",
        "letrozole",
        "treatment",
        "percent",
        "john",
        "food",
        "administration",
        "form",
        "business",
        "drugnovartis",
        "stable",
        "blockbuster",
        "potential",
        "revenue",
        "thomson",
        "biotech",
        "part",
        "otsuka",
        "structure",
        "protein",
        "kisqaliapproval",
        "lee011",
        "combination",
        "hormone",
        "receptor",
        "growth",
        "factor",
        "hrher2",
        "mondaythe",
        "jumpoff",
        "point",
        "patientsibrance",
        "discount",
        "dosingleerink",
        "analyst",
        "seamus",
        "fernandez",
        "note",
        "pricing",
        "takeup",
        "cost",
        "qt",
        "prolongation",
        "heart",
        "liver",
        "wrotenovartis",
        "efficacy",
        "safety",
        "health",
        "interrupting",
        "dosekisqali",
        "risk",
        "disease",
        "progression",
        "death",
        "study",
        "review",
        "reporting",
        "ben",
        "hirschler",
        "editing",
        "goodman"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}